sic2026.cancerologia.it Don’t miss the opportunity to share your research in an inclusive and exciting meeting! We hope to meet you all in Rome at #SIC_2026

If you are interested in PARP inhibitors and history, this might be of interest to you. www.nature.com/articles/s41.... An attempt to cover the work of thousands and their immense contributions to the development of a targeted approach to treating cancers.

Epithelial ovarian cancer frequently recurs and becomes resistant to platinum chemotherapy. In our latest issue, two separate phase 3 trials highlight two potential new treatments for platinum-resistant ovarian cancer. Read this & more ▶️ spkl.io/63325A4OfN

A comprehensive analysis of cyclin-dependent kinases in #CellCycle regulation, detailing how their dysregulation drives disease and evaluating the therapeutic potential of targeted CDK inhibitors. @gusbald.bsky.social @gustavo_baldassarre #OpenAccess: doi.org/10.1038/s413...

Lev Tolstoj, Resurrezione.

A review of the functions of human #CyclinDependentKinases, highlighting their roles in #cellcycle control, disease progression, & the therapeutic potential of #CDKInhibitors in #cancer & other diseases. @gusbald.bsky.social #STTT: doi.org/10.1038/s413...

Great presentation at #CRO_Aviano_IRCCS by @biancastellac.bsky.social on genetic and #epigenetic alterations in #breast tissue. Thank you Biancastella, it was wonderful have you in Aviano!

This review summarizes the functions of #CyclinDependentKinases (CDKs), discusses their potential roles and deregulation in human pathologies and underscores the role of CDK inhibitors as standard therapies in #cancer. #medsky @gusbald.bsky.social @gustavo_baldassarre #OpenAccess: buff.ly/NA2B1Fs

Sunset from #Monte_Faito #Campania #Italy. From right to left you can admire the Vesuvius Vulcan, Monte di Procida, the islands Procida, Ischia and Capri and the peninsula Sorrentina. This is the magnificent #gulf_of_Napoli

Sunrise at #Scilla #Calabria Italy! Just beautiful!!

Just out in #Molecular_Cancer a beautiful journey with Ivana de la Serna and Francois Vallette discussing #cancer_cells #clonal_evolution and #resistance to treatments from 3 different and complementary points of view. Hope you will enjoy read this review as we enjoyed writing it. rdcu.be/emfur

Free registration open for BIG2025. Limited on site places. All info on: 👇 ecm.meetingsrl.eu/BIG2025/defa... Registration for ITALIAN PARTICIPANT 👇 ecm.meetingsrl.eu/BIG2025/defa... Registration forFOREIGN PARTICIPANT 👇 www.meetingsrl.eu/registration... Meet the speakers See you in Venice

Free registration open for BIG2025. Limited on site places. All info on: 👇 ecm.meetingsrl.eu/BIG2025/defa... Registration for ITALIAN PARTICIPANT 👇 ecm.meetingsrl.eu/BIG2025/defa... Registration forFOREIGN PARTICIPANT 👇 www.meetingsrl.eu/registration... Meet the speakers

Here we are! Registration for BIG 2025 is now open. All info on: 👇 ecm.meetingsrl.eu/BIG2025/defa... Registration for ITALIAN PARTICIPANT 👇 ecm.meetingsrl.eu/BIG2025/defa... Registration forFOREIGN PARTICIPANT 👇 www.meetingsrl.eu/registration... See you in Venice

Beautiful manuscript just published in @nature.com suggesting that a shorter #cell_cycle duration is associated to a higher possibility of cell transformation. Here is the link👇🏻 rdcu.be/ek1vB

The 4th edition of BIG is approaching. An exceptional panel of speakers discussing the novelties in #translational and #clinical #gynecology_oncology. Free registration but limited places. Below, you can see the venue and meet the organizers. Stay tuned for updates. See you in #Venice

Safeguarding the future of biomedical science in the United States: Cell www.cell.com/cell/fulltex...

90% of people diagnosed with pancreatic cancer die from the disease. That's why the medical community is excited about the results of a small trial in which nearly half of the pancreatic cancer patients who received an mRNA vaccine for the disease remained relapse-free three years later.

new out in @nature.com www.nature.com/articles/s41...

The 4th edition of BIG is approaching. Don’t miss the opportunity to joining us and meet an exceptional panel of speakers in the wonderful city of Venice. Stay tuned for further updates

7 new Cancer Grand Challenges announced: www.cancergrandchallenges.org/new-challenges @cancergrand.bsky.social

Right now, I can't open: www.nlm.nih.gov ftp.ncbi.nlm.nih.gov www.ncbi.nlm.nih.gov www.ncbi.nlm.nih.gov/genbank/ pubmed.ncbi.nlm.nih.gov

As we can expect PubMed dysfunction more and more or to be swamped with fake journals I suggest you get acquainted to this nice alternative: europepmc.org

Remember, EuropePMC is actually better than #PubMed because it includes ALL preprints in search results, not just those including NIH-funded research. europepmc.org

Enjoying skiing on Dolomiti alps in a sunny, cold Saturday with old friends! What a day!

What a great start to 2025 having our review on the role of hashtag#CDKs in human physiology and diseases just published in #Signal_Transduction_Targeted_Therapies! Here is the link to the open access article 👇 rdcu.be/d6a4g A big effort of the lab but we learnt a lot! I hope you will enjoy it

What a great start to 2025 having our review on the role of hashtag#CDKs in human physiology and diseases just published in #Signal_Transduction_Targeted_Therapies! Here is the link to the open access article 👇 rdcu.be/d6a4g A big effort of the lab but we learnt a lot! I hope you will enjoy it

Cyclin Dependent Kinases (CDKs) are crucial for cell division and exist in 20 variations, each with unique roles. Their malfunction is linked to diseases like cancer and Alzheimer's. CDK inhibitors are now cancer treatments, and exploring their use in other diseases could help improve patient care.

Scientists in Italy show how cyclin-dependent kinases (CDKs) regulate cell division, gene expression, and DNA repair. Disrupted CDKs fuel diseases like cancer, making them critical targets for therapy. www.nature.com/articles/s41...

This paper is the result of an incredibly fun collaboration with Sandro Santagata and Peter Sorger. Led by an amazing postdoc @tanjinakader.bsky.social and JiaRen Lin, we provide a pre-cancer atlas of Fallopian tube precursors to High-Grade Serous Ovarian Cancer. The data is also on cbioportal!

Interesting paper now published in Science👇🏻 www.science.org/doi/10.1126/...

Now online in Cancer Discovery: Multimodal Spatial Profiling Reveals Immune Suppression and Microenvironment Remodeling in Fallopian Tube Precursors to High-Grade Serous Ovarian Carcinoma - by Tanjina Kader, Jia-Ren Lin, Clemens Hug, Ronny Drapkin, Sandro Santagata, et al. doi.org/10.1158/2159...

Il mondo novax ha costruito una intera narrazione sull'efficacia e utilità dell'idrossiclorochina e azitromicina contro COVID-19. Ora lo studio "Principe" è stato ritirato.

Using #PDX and #Organoids to study CDK4/6 inhibitors resitance in #breast_cancer. A new beautiful work by @bbelletti.bsky.social and collaborators 👇 pathsocjournals.onlinelibrary.wiley.com/share/D7UDHP...

The new metro station of Chiaia #Naples, #Italy

Interesting review on targeted protein degradation rdcu.be/d3VEx

Today we celebrate the first 40 years of our institute Centro di Riferimento Oncologico CRO-Aviano National Cancer Institute. 40 beautiful years of research and cure in oncology in which we witnessed the advancements in the care for our patients.

The SAFE project accepts applications for 60 fellowships for at-risk non-EU researchers (PhD/postdoc) to join research institutions in the EU. 🌍 Matchmaking support until 15 December 📅 Deadline: 20 Jan 2025 🔗 Learn more: saferesearchers.eu #ResearchOpportunities #AtRiskResearchers #SAFEFellowship

Delaying and shortening the duration of treatment with CDK4/6 inhibitors in patients with metastatic breast cancer leads to similar survival outcomes while reducing toxicity and achieving substantial cost savings, the SONIA trial shows. Read more ➡️ bit.ly/3Oqw7aX

Emerging strategies to investigate the biology of early cancer www.nature.com/articles/s41...

From @seedgeorge.bsky.social Johann De Bono and colleagues (us !). In BRCA2m CRPC, reversion mutations emerge in 79% by end of olaparib treatment. Reversions associate with PFS and OS. Rare subclones without BRCA2-loss also emerge authors.elsevier.com/sd/article/S...

After a sold-out 2023 event, Goodbye Flat Biology has moved to a larger venue in Essen, Germany to make sure more of you can join us for what promises to be another fantastic event! Join us for 3 days of excellent science and networking: eacr.org/conference/g...

I'm also trying to survive ovarian cancer, and research funds have been traditionally been so minimal for this disease. JJDiane, find ocrahope.org if you're not already familiar with it. Let's keep advocating together!

Announcing the next EMBO Chromosome Segregation and Aneuploidy Meeting! Italy 2025. Please register and join us for another exciting and friendly meeting in a beautiful location meetings.embo.org/event/25-ane...

Happy to share on Bluesky as my first post our new study on #chemoresistance in #ovarian-cancer just published in #Science_Advances. We show that #USP1 binds and regulates the activity of #PARP1 and that their combined inhibition sinergistically kills cancer cells.👇 www.science.org/doi/10.1126/...